Rising to the challenge: New therapies for tuberculosis

Research output: Contribution to journalReview articlepeer-review

60 Scopus citations


The standard treatment for tuberculosis (TB) is lengthy, complex, and significantly toxic. Drug development for TB has stagnated for decades, but in recent years renewed commitment and coordinated research has generated a modest pipeline of new drugs that hold the potential to make treatment more effective, shorter, less complex, and less toxic in the near future. With a particular focus on bedaquiline (TMC207), the first anti-TB drug of a novel class to be approved by the US Food and Drug Administration (FDA) in 40 years, this review summarizes the recent evidence behind new developments in TB treatment. Novel drug classes, repurposed drugs, and host-directed therapies are reviewed. In parallel to these exciting developments in drug discovery, we propose that it is crucial to develop more rapid and comprehensive diagnostics that will allow the timely selection of the best regimen for individual patients.

Original languageEnglish (US)
Pages (from-to)493-501
Number of pages9
JournalTrends in Microbiology
Issue number9
StatePublished - Sep 2013


  • Bedaquiline
  • Clofazimine
  • Delamanid
  • Oxazolidinones
  • PA-824
  • Tuberculosis

ASJC Scopus subject areas

  • Microbiology
  • Microbiology (medical)
  • Infectious Diseases
  • Virology


Dive into the research topics of 'Rising to the challenge: New therapies for tuberculosis'. Together they form a unique fingerprint.

Cite this